status, the incidence of complications, and completion rate of radiotherapy were evaluated. Besides, the length of hospital stay （LOS） and the in-patient cost were also compared between these two groups. Results： A...status, the incidence of complications, and completion rate of radiotherapy were evaluated. Besides, the length of hospital stay （LOS） and the in-patient cost were also compared between these two groups. Results： At the completion of CRF, the nutritional status in the NST group were much better than those in the control group, as evidenced by prealbumin （ALB）, transferrin, and ALB parameters （P = 0.001, 0.000, and 0.000, respectively）. The complication incidences, including bone marrow suppression （20% vs. 48%, P = 0.037） and complications related infections （ 12% vs. 44%, P = 0.012）, in the NST group were lower and significantly different from the control group. In addition, only one patient in the NST group did not complete the planned radiotherapy while 6 patients in the control group had interrupted or delayed radiotherapy （96% vs. 76%, P - 0.103）. Furthemlore, the average LOS was decreased by 4.5 days （P = 0.001 ） and in-patient cost was reduced to 1.26 ± 0.75 thousand US dollars person-times （P 〉 0.05） in the NST group. Conelusions： A NST could provide positive effects in esophageal cancer patients during concurrent CRT on maintaining their nutrition status and improving the compliance of CRF. Moreover, the NST could be helpful on reducing LOS and in-patient costs.展开更多
Lung cancer is the leading cause of cancer death worldwide.Majority of newly diagnosed lung cancers are non-small cell lung cancer(NSCLC), of which up to half are considered locally advanced at the time of diagnosis.P...Lung cancer is the leading cause of cancer death worldwide.Majority of newly diagnosed lung cancers are non-small cell lung cancer(NSCLC), of which up to half are considered locally advanced at the time of diagnosis.Patients with locally advanced stage Ⅲ NSCLC consists of a heterogeneous population, making management for these patients complex.Surgery has long been the preferred local treatment for patients with resectable disease.For select patients, multimodality therapy involving systemic and radiation therapies in addition to surgery improves treatment outcomes compared to surgery alone.For patients with unresectable disease, concurrent chemoradiation is the preferred treatment.More recently, research into different chemotherapy agents, targeted therapies, radiation fractionation schedules, intensity-modulated radiotherapy, and proton therapy have shown promise to improve treatment outcomes and quality of life.The array of treatment approaches for locally advanced NSCLC is large and constantly evolving.An updated review of past and current literature for the roles of surgery, chemotherapeutic agents, radiation therapy, and targeted therapy for stage Ⅲ NSCLC patients are presented.展开更多
文摘status, the incidence of complications, and completion rate of radiotherapy were evaluated. Besides, the length of hospital stay （LOS） and the in-patient cost were also compared between these two groups. Results： At the completion of CRF, the nutritional status in the NST group were much better than those in the control group, as evidenced by prealbumin （ALB）, transferrin, and ALB parameters （P = 0.001, 0.000, and 0.000, respectively）. The complication incidences, including bone marrow suppression （20% vs. 48%, P = 0.037） and complications related infections （ 12% vs. 44%, P = 0.012）, in the NST group were lower and significantly different from the control group. In addition, only one patient in the NST group did not complete the planned radiotherapy while 6 patients in the control group had interrupted or delayed radiotherapy （96% vs. 76%, P - 0.103）. Furthemlore, the average LOS was decreased by 4.5 days （P = 0.001 ） and in-patient cost was reduced to 1.26 ± 0.75 thousand US dollars person-times （P 〉 0.05） in the NST group. Conelusions： A NST could provide positive effects in esophageal cancer patients during concurrent CRT on maintaining their nutrition status and improving the compliance of CRF. Moreover, the NST could be helpful on reducing LOS and in-patient costs.
文摘Lung cancer is the leading cause of cancer death worldwide.Majority of newly diagnosed lung cancers are non-small cell lung cancer(NSCLC), of which up to half are considered locally advanced at the time of diagnosis.Patients with locally advanced stage Ⅲ NSCLC consists of a heterogeneous population, making management for these patients complex.Surgery has long been the preferred local treatment for patients with resectable disease.For select patients, multimodality therapy involving systemic and radiation therapies in addition to surgery improves treatment outcomes compared to surgery alone.For patients with unresectable disease, concurrent chemoradiation is the preferred treatment.More recently, research into different chemotherapy agents, targeted therapies, radiation fractionation schedules, intensity-modulated radiotherapy, and proton therapy have shown promise to improve treatment outcomes and quality of life.The array of treatment approaches for locally advanced NSCLC is large and constantly evolving.An updated review of past and current literature for the roles of surgery, chemotherapeutic agents, radiation therapy, and targeted therapy for stage Ⅲ NSCLC patients are presented.
